Weekly round-up: Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, on Friday announced that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Synaffix B.V., a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, on Monday announced that it has licensed its ADC technology to BigHat Biosciences, Inc.
BigHat will combine Synaffix’s technology with its world-class artificial intelligence/machine learning powered antibody design platform, Milliner™, for the development of a new ADC pipeline program.
Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, on Tuesday announced that it has appointed Luc Verhees as its new Vice President of Clinical Business Development.
Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
Poolbeg Pharma, a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, on Wednesday announced it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the ASH Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California.
Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
Heidelberg Pharma AG, a clinical-stage developer of innovative ADCs, on Wednesday announced that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the ASH Annual Meeting.
Why ‘healthspan’ is a vital new concept in life science investing
At the Optimum Strategic Communications’ 16th Annual Healthcare Investor Conference, held on Thursday 10th October 2024 at The King’s Fund, London, Dr Mehmood Khan, CEO of the Kingdom of Saudi Arabia’s Hevolution Foundation, spoke to Clive Cookson, Senior Science Writer at the Financial Times, about the importance of investing in “healthspan”. Check out our article summarising Dr Khan’s thoughts here.
Optimum Perspectives Podcast
In the latest podcast episode to mark Lung Cancer Awareness Month, Optimum’s Richard Staines spoke to Roman Thomas, CEO and founder of DISCO Pharmaceuticals, on breakthroughs that have improved patient outcomes, and the company’s efforts to help develop new therapies with its “surfaceome” technology.
Listen to the full episode here!
